Antibodies are an important class of biotherapeutics. The process of engineering a therapeutic antibody is time and cost intensive, with many of them failing due to developability issues, such as low expression, low solubility, and high aggregation. My research aims to develop computational methods to improve the outputs of antibody developability workflows. These tools will incorporate experimental data including negative data, which is essential to guide the antibody engineering process.